Reporter brief
Phase II RCT of metformin examined aging markers in middle-aged and elderly adults
What happened
A Phase II randomized controlled trial investigated whether oral metformin could slow aging processes in middle-aged and elderly people. The study aimed to identify sensitive markers of aging and develop frameworks for anti-aging interventions, though specific findings, sample size, and effect sizes were not reported in the available information.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Middle-aged and elderly males
- Design
- Rct
- Sample
- —
- Journal
- Xuanwu Hospital, Beijing
- Published
- Mar 21, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.